Trial shows Lilly’s Zepbound helps patients lose far more weight than competing drug
Eli Lilly and Co. said Wednesday morning that its weight-loss treatment Zepbound helped patients lose 47% more relative weight than competitor Novo Nordisk’s obesity treatment Wegovy in a head-to-head clinical trial.... Read More